Document is current
Any future updates will be listed below
-
Authors
To, Ciric https://orcid.org/0000-0002-6333-3174
Beyett, Tyler S. https://orcid.org/0000-0001-5509-7004
Jang, Jaebong
Feng, William W. https://orcid.org/0000-0002-8976-5020
Bahcall, Magda
Haikala, Heidi M.
Shin, Bo H.
Heppner, David E. https://orcid.org/0000-0002-0722-5160
Rana, Jaimin K.
Leeper, Brittaney A.
Soroko, Kara M.
Poitras, Michael J.
Gokhale, Prafulla C. https://orcid.org/0000-0002-1974-5921
Kobayashi, Yoshihisa https://orcid.org/0000-0003-2057-408X
Wahid, Kamal
Kurppa, Kari J.
Gero, Thomas W.
Cameron, Michael D.
Ogino, Atsuko
Mushajiang, Mierzhati
Xu, Chunxiao
Zhang, Yanxi
Scott, David A. https://orcid.org/0000-0003-3243-528X
Eck, Michael J. https://orcid.org/0000-0003-4247-9403
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Jänne, Pasi A. https://orcid.org/0000-0002-7821-4928
- License Information
-
More Information
Article History
Received: 18 April 2021
Accepted: 23 February 2022
First Online: 14 April 2022
Competing interests
: P.A.J. has received consulting fees from AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Takeda Oncology, ACEA Biosciences, Eli Lilly and Company, Araxes Pharma, Ignyta, Mirati Therapeutics, Novartis, LOXO Oncology, Daiichi Sankyo, Sanofi Oncology, Voronoi, SFJ Pharmaceuticals, Biocartis, Novartis Oncology, Nuvalent, Esai, Bayer, Transcenta, Silicon Therapeutics, Allorion Therapeutics, Accutar Biotech and AbbVie; receives post-marketing royalties from DFCI-owned intellectual property on EGFR mutations licensed to Lab Corp; receives or has received sponsored research funding from AstraZeneca, Astellas, Daichi-Sankyo, PUMA, Boehringer Ingelheim, Eli Lilly and Company, Revolution Medicines and Takeda and has stock ownership in Gatekeeper Pharmaceuticals. N.S.G. is a founder, science advisory board member and equity holder in Gatekeeper, Syros, Petra, C4, Allorion, Jengu, B2S, Inception, EoCys, Larkspur (board member) and Soltego (board member). The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield and Sanofi. M.J.E. has served as a paid consultant to Novartis Institutes for Biomedical Research and H3 Biomedicine. M.J.E. receives sponsored research support from Novartis, Sanofi and Takeda. D.E.H. is a consultant for Logos Capital and the Jefferies Group. The series of compounds to which JBJ-04-125-02 and JBJ-09-063 belong is described in US patent 10,836,722 B2. All other authors declare no competing interests.
